How to Find the Best Small-Cap Stocks to Buy
Wall Street's best small-cap stocks to buy include biotech, real estate and industrials names.
The second half of 2024 could be much more favorable for stockpickers looking for the best small-cap stocks to buy.
That might sound counterintuitive after the way small caps performed through the first half of the year. After all, small caps as an asset class have been a dud. They went nowhere as mega-cap stocks pushed the broader market to record highs seemingly every other day.
To recap: the S&P 500 gained almost 15% on a price basis through the first half of the year, while the tech-heavy Nasdaq Composite rose nearly 18%. The Dow Jones Industrial Average rose just 4%, hurt by its price-weighted construction.
Sign up for Kiplinger’s Free E-Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
But while select Magnificent 7 stocks such as Nvidia (NVDA), Apple (AAPL) and Microsoft (MSFT) drove the majority of the market's gains, small caps – which tend to be more sensitive to the economic cycle and interest rates – traded sideways. Indeed, the small-cap benchmark Russell 2000 Index – struggling to stay positive for months – was slightly negative as we closed out the first half.
"Since the bull market began, a glaring feature has been the dominance of large caps (proxied by the S&P 500) and the lack of meaningful upside for small caps (proxied by the Russell 2000)," writes Liz Ann Sonders, chief investment strategist at Charles Schwab. "We think the fact that higher rates are putting more pressure on small companies' profitability is driving the performance gap."
Small-cap stocks are cheap
If there is a sliver of a silver lining to the Russell 2000's underperformance, it's that small caps are now trading at bargain basement prices.
"Small caps stocks are historically cheap versus just about every other equity asset class," writes Grant Engelbart, investment strategist at Carson Group. "While this large valuation discount does not provide any sense of timing, it is still a tailwind for the asset class."
The strategist adds that small company earnings growth appears to have "troughed over the past year, setting up future year expectations in a big way." According to current estimates, analysts see small-cap earnings growth surpassing that of S&P 500 companies in 2025 and 2026.
And with the Federal Reserve expected to enact at least one quarter-point cut to the federal funds rate before year-end, small caps should have at least one catalyst on the horizon.
Best small-caps stocks to buy
In order to find the best small-cap stocks to buy now, we started by screening the Russell 2000 for Wall Street analysts' top-rated names.
Here's how the process works: S&P Global Market Intelligence surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell. Any score of 2.5 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call.
In other words, lower scores are better than higher scores.
We further limited ourselves to stocks with at least 10 Strong Buy recommendations (in order to ensure adequate analyst coverage and sample size). Lastly, we dug into research, fundamental factors, valuation, analysts' estimates and other data on the top names.
Our screen of the Street's best small-cap stocks served up a list dominated by the healthcare sector, mostly pharmaceutical and biotechnology companies. That's to be expected, and investors should always do their own due diligence when considering, say, a clinical-stage biotech firm, which is essentially a speculative investment.
In other cases, some of these names – a couple of industrials stocks and a REIT – might just surprise you.
And with that, have a look at the table below to see Wall Street's best small-cap stocks to buy now.
Company (Ticker) | Sector | Analysts' Consensus Recommendation Score | Analysts' Consensus Recommendation |
---|---|---|---|
BrightSpring Health Services (BTSG) | Healthcare | 1.17 | Strong Buy |
Parsons (PSN) | Industrials | 1,18 | Strong Buy |
Immunovant (IMVT) | Biotechnology | 1.27 | Strong Buy |
Enovix (ENVX) | Industrials | 1.31 | Strong Buy |
Insmed (INSM) | Biotechnology | 1.31 | Strong Buy |
Rocket Pharmaceuticals (RCKT) | Biotechnology | 1.33 | Strong Buy |
Arcellx (ACLX) | Biotechnology | 1.35 | Strong Buy |
Kura Oncology (KURA) | Biotechnology | 1.36 | Strong Buy |
Essential Properties Realty Trust (EPRT) | Real Estate | 1.36 | Strong Buy |
Axsome Therapeutics (AXSM) | Pharmaceuticals | 1.38 | Strong Buy |
Get Kiplinger Today newsletter — free
Profit and prosper with the best of Kiplinger's advice on investing, taxes, retirement, personal finance and much more. Delivered daily. Enter your email in the box and click Sign Me Up.
Dan Burrows is Kiplinger's senior investing writer, having joined the august publication full time in 2016.
A long-time financial journalist, Dan is a veteran of SmartMoney, MarketWatch, CBS MoneyWatch, InvestorPlace and DailyFinance. He has written for The Wall Street Journal, Bloomberg, Consumer Reports, Senior Executive and Boston magazine, and his stories have appeared in the New York Daily News, the San Jose Mercury News and Investor's Business Daily, among other publications. As a senior writer at AOL's DailyFinance, Dan reported market news from the floor of the New York Stock Exchange and hosted a weekly video segment on equities.
Once upon a time – before his days as a financial reporter and assistant financial editor at legendary fashion trade paper Women's Wear Daily – Dan worked for Spy magazine, scribbled away at Time Inc. and contributed to Maxim magazine back when lad mags were a thing. He's also written for Esquire magazine's Dubious Achievements Awards.
In his current role at Kiplinger, Dan writes about equities, fixed income, currencies, commodities, funds, macroeconomics, demographics, real estate, cost of living indexes and more.
Dan holds a bachelor's degree from Oberlin College and a master's degree from Columbia University.
Disclosure: Dan does not trade stocks or other securities. Rather, he dollar-cost averages into cheap funds and index funds and holds them forever in tax-advantaged accounts.
-
States That Won't Tax Your Retirement Income in 2025
Retirement Taxes Several states don’t tax Social Security benefits, 401(k)s, IRAs, and pensions. But you may still have to pay state taxes on some incomes.
By Kate Schubel Published
-
Build Your Dream Retirement With These Five Steps
Dreaming about life after work? Turn your dreams into a concrete, actionable plan by nailing down the why, what and how of your retirement.
By Keith Wiltfong, CFP®, CIMA® Published
-
Build Your Dream Retirement With These Five Steps
Dreaming about life after work? Turn your dreams into a concrete, actionable plan by nailing down the why, what and how of your retirement.
By Keith Wiltfong, CFP®, CIMA® Published
-
For Investors, 2024 Was a Year to Remember
A perfect storm of favorable conditions created a rewarding landscape for investors. A buzz of cautious optimism continues for 2025.
By Stacy Francis, CFP®, CDFA®, CES™ Published
-
Here's How Retirement Changes Your Taxes
How you approach taxes in your golden years and in the years before retirement can dramatically impact how much you pay.
By Joel V. Russo, LUTCF Published
-
Stock Market Today: Trump Tariff Worries Pressure Stocks
Stocks swung lower Friday after the White House confirmed it will impose tariffs on Mexico, Canada and China beginning tomorrow.
By Karee Venema Published
-
Chevron Stock Declines Despite Another Dividend Hike
Chevron stock is down Friday after the integrated energy company missed fourth-quarter profit expectations. Here's what you need to know.
By Joey Solitro Published
-
Why Walgreens Suspended Its Dividend
Walgreens stock is spiraling Friday after the pharmacy chain suspended its dividend amid continued turnaround plans. Here's what you need to know.
By Joey Solitro Published
-
Intel Earnings Do Little to Excite Investors: What to Know
Intel stock is struggling for direction Friday after the chipmaker reported a fourth-quarter beat but gave weak guidance. Here's what Wall Street has to say.
By Joey Solitro Published
-
Visa Stock Rises on Strong Earnings, Bullish Outlook
Visa stock is up Friday after the payments company beat expectations for its fiscal 2025 first quarter and raised its outlook. Here's what you need to know.
By Joey Solitro Published